Physician profile
Bassel Hadaya
NPI 1174629950
$3,772.26
in general payments reported to CMS, 2019-2025
23 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $297 · 2021: $442 · 2022: $513 · 2023: $703 · 2024: $701 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $873.01 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $424.57 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Glaxosmithkline, LLC. | $286.79 | 2021-2025 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $273.93 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $244.54 | 2019-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $228.25 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $220.37 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $216.01 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $167.52 | 2020-2025 | Acthar |
| Genzyme Corporation | $157.65 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $99.63 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $91.22 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $87.45 | 2022-2025 | Tarpeyo |
| Biotronik INC. | $69.45 | 2022 | |
| Daiichi Sankyo INC. | $60.09 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $54.38 | 2021-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $51.46 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $47.28 | 2019 | |
| Ardelyx, INC. | $34.65 | 2023-2024 | Ibsrela |
| Cormedix INC. | $28.21 | 2025 | Defencath |
| Janssen Pharmaceuticals, INC | $26.93 | 2019 | |
| Vifor Pharma, INC. | $23.05 | 2019 | |
| Travere Therapeutics, INC. | $5.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Hadaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.